Bone Metastases Clinical Trial
Official title:
The Evaluation of the Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic Castration-resistant Prostate Cancer Patients Treated With Radium-223 Therapy, a Multicenter, Prospective Observational Cohort Study
The aim of the current prospective multicenter study is to evaluate cancer-specific and bone metastases related HR-QoL, psychological distress and fatigue in mCRPC patients before, during and after treatment with radium-223 in daily practice. Furthermore, the investigators aim to determine patient groups with identical health-related quality of life patterns over time, in order to identify variables related to health-related quality of life deterioration during the course of treatment, as patients with health-related quality of life deterioration may need specific attention to preserve health-related quality of life.
Radium-223 is a registered treatment option for patients with symptomatic bone metastatic castration-resistant prostate cancer. Previously, the phase 3 ALSYMPCA trial demonstrated that radium-223 improved overall survival and prolonged the time to the first symptomatic skeletal event and the time to first opioid use, irrespective of prior docetaxel chemotherapy. Subsequent analysis of the ALSYMPCA study showed that a significantly higher percentage of patients receiving radium-223 experienced meaningful HR-QoL improvement, as measured by the EQ-5D questionnaire and the FACT-P questionnaire, when compared to patients treated with placebo. However, studies evaluating health-related quality of life, psychological distress and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 in daily practice are lacking. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03986593 -
Cryoablation of Bone Metastases From Endocrine Tumors
|
N/A | |
Active, not recruiting |
NCT01996046 -
FDG PET/CT in Breast Cancer Bone Mets
|
||
Completed |
NCT01358539 -
Palliation: the Effect of Education on Pain
|
Phase 3 | |
Terminated |
NCT00981578 -
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
|
N/A | |
Terminated |
NCT00757757 -
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
|
Phase 1/Phase 2 | |
Completed |
NCT00762346 -
Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis
|
Phase 4 | |
Completed |
NCT00420433 -
Bone Response in Metastatic Breast Cancer Involving Bones
|
N/A | |
Completed |
NCT02826382 -
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
|
Early Phase 1 | |
Terminated |
NCT05301062 -
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
|
||
Recruiting |
NCT06367491 -
National Database of Bone Metastases
|
||
Completed |
NCT03223727 -
Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
|
||
Completed |
NCT00830180 -
Open Label Extension In Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03305224 -
The Combination Therapy With Ra-223 and Enzalutamide
|
Phase 2 | |
Withdrawn |
NCT04109937 -
External Beam Radiation Therapy Post Surgery in Patients With Lower Extremity Bone Metastases Randomized Efficacy Trial
|
N/A | |
Active, not recruiting |
NCT02880943 -
Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)
|
Phase 1/Phase 2 | |
Completed |
NCT01696760 -
Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
|
N/A | |
Completed |
NCT00958477 -
A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer
|
Phase 1 | |
Completed |
NCT03979118 -
Exercise Prescription in Patients With Bone Metastases
|
||
Completed |
NCT03353090 -
Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients
|
N/A | |
Recruiting |
NCT05167669 -
Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU
|
Early Phase 1 |